Supplementary material for the financial results for the second quarter of the year ending March 31, 2023

November 2022


(Stock code: 4553)



C Copyright 2022 TOWA PHARMACEUTICAL CO., LTD. All Rights Reserved.

Notes the details of the disclosure of financial results for 2023/03 2Q

- Sunsho Pharmaceutical Co., Ltd. ("Sunsho Pharmaceutical"), which became a subsidiary in March 2022, <u>has been included in the consolidated balance sheets since 2022/03 and the consolidated</u> <u>statements of income since 2023/03</u>.
- The first half period for Towa HD and Sunsho Pharmaceutical is from January 1 to June 30, 2022.
- Regarding our earnings forecast for 2023/03, we revised our consolidated earnings forecast for the second quarter on November 7 and our full-year consolidated earnings forecast on November 14.



OWA HARMACEUTICAL

- 1. Outline of financial results for 2023/03 2Q
- 2. Outline of financial results for 2023/03 2Q Progress rate
- 3. Balance sheets, capital expenditure and depreciation
- 4. Revisions to earnings plan for 2023/03



Contents

1. Outline of financial results for 2023/03 2Q

- Consolidated Segment information
 - **Domestic segment**
 - Breakdown

Net sales by supplement year (Non-consolidated)

Net sales by distribution channel (Non-consolidated)

Number of customers by customer segment (Non-consolidated)

Selling, general and administrative expenses (Domestic segment)

Overseas segment

By region

2. Outline of financial results for 2023/03 2Q – Progress rate

3. Balance sheets, capital expenditure and depreciation

4. Revisions to earnings plan for 2023/03



Outline of financial results for 2023/03 2Q (Consolidated)

- Net sales : Increased due to the consolidation of Sunsho Pharmaceutical and strength in Europe despite weakness at Towa Pharmaceutical in Japan
- Operating profit : Decreased due to a drop in gross margin resulting from a rise in the cost of sales ratio in Japan and increase in SGA, e.g., goodwill amortization, following the acquisition of Sunsho Pharmaceutical

Fiscal per	riod		2023/03 2Q			2022/03 2Q	
Item		(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)
Net sale	es	90,500	100.0	+ 10.0	82,254	100.0	+ 10.2
Cost of sa	ales	57,325	63.3	+ 22.3	46,876	57.0	+ 7.0
SGA		29,954	. 33.1	+ 19.5	25,066	30.5	+ 14.3
Operating p	orofit	3,220	3.6	- 68.8	10,312	12.5	+ 15.7
Ordinary p	orofit	4,609	5.1	- 64.6	13,008	15.8	+ 46.9
	Profit attributable to owners of parent		3.0	- 70.9	9,242	11.2	+ 44.8
Exchange	2023/0	03 2Q 22/3	4Q 22/3 2Q	21/3 4Q	Exchange rate	,	22/3 2Q
rate at end of period (TTM) USD 1	JPY 1	44.81 JPY 12	2.39 JPY 111.92	2 JPY 110.71	during period (TTM) EUR 1	JPY 134.25	JPY 129.82

Notes: 1. The first half period for Towa HD and Sunsho Pharmaceutical is from January 1 to June 30, 2022.

2. For 2023/03 2Q, the USD/JPY exchange rate at the end of the period is the rate as of September 30, 2022, and the EUR/JPY exchange rate during the period is the average rate from April 1 to June 30, 2022.



Outline of financial results for 2023/03 2Q (Segment information)

(JPY million)

	R	eportable segme	nt			
	Domestic	Overseas			Consolidated	
Item	Towa Pharmaceutical J-Dolph Pharmaceutical Daichi Kasei Greencaps Pharmaceutical Sunsho Pharmaceutical	Towa HD	Total	Adjustment (Goodwill amortization)		
Net sales	70,597	19,902	90,500	-	90,500	
Cost of sales	43,759	13,565	57,325	-	57,325	
SGA	21,789	6,119	27,909	2,045	29,954	
Segment profit	5,048	217	5,265	△ 2,045	3,220	

Notes: 1. Goodwill amortization: Towa HD JPY 414 million; Sunsho Pharmaceutical JPY 1,630 million

2. The first half period for Towa HD and Sunsho Pharmaceutical is from January 1 to June 30, 2022.

Outline of financial results for 2023/03 2Q (Domestic segment)

- Net sales : Increased due to consolidation of Sunsho Pharmaceutical despite weakness at **Towa Pharmaceutical**
- Segment profit : Decreased due to a rise in the cost of sales ratio as a result of the consolidation of Sunsho Pharmaceutical, which has a high cost of sales ratio, and to the impact of drug price revisions and an increase in SGA (JPY million, %)

Fiscal period	Domestic segment (Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical, Sunsho Pharmaceutical)										
r iscal period		2023/03 2Q		2022/03 2Q							
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)					
Net sales	70,597	100.0	+ 10.3	63,984	100.0	+ 14.4					
Cost of sales	43,759	62.0	+ 25.6	34,831	54.4	+ 15.1					
SGA	21,789	30.9	+ 16.4	18,714	29.2	+ 12.6					
Segment profit	5,048	7.2	- 51.6	10,438	16.3	+ 15.5					

Note: The first half period for Sunsho Pharmaceutical is from January 1 to June 30, 2022.

OWA

Outline of financial results for 2023/03 2Q (Domestic segment, breakdown)

Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical

- Net sales : Decreased due to a decline in prices of existing drugs following drug price revisions, and a drop in sales volume as a result of limited shipment of some products, while sales volume increased significantly in the same period last year due to market demand for stable supply
- Segment profit : Decreased due to a drop in sales and a drop in gross margin as a result of price declines following drug price revisions, and to a rise in the cost of sales ratio owing to deterioration of the sales mix. SGA also increased.

(J	۶Y	mil	lion,	%)
----	----	-----	-------	----


Fiscal period	Towa Ph	armaceut Kasei, G	Sunsho Pharmaceutical							
	2	023/03 2Q		20	22/03 2Q		2023/0	2023/03 2Q		
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)		
Net sales	60,200	100.0	- 5.9	63,984	100.0	+ 14.4	10,397	100.0		
Cost of sales	35,790	59.5	+ 2.8	34,831	54.4	+ 15.1	7,969	76.6		
SGA	20,292	33.7	+ 8.4	18,714	29.2	+ 12.6	1,496	14.4		
Segment profit	4,117	6.8	- 60.6	10,438	16.3	+ 15.5	931	9.0		

Notes: 1. The first half period for Sunsho Pharmaceutical is from January 1 to June 30, 2022.

2. Goodwill amortization is not included.



Net sales by supplement year (Non-consolidated)



Net sales by distribution channel (Non-consolidated)



Direct sales Sales agent Wholesaler Other (consignment, sales by other companies, exports) Figures in brackets are number of sales offices

9

(Customer, %)

	Customer segment				2023/03 20	ב		2022/03 2Q		
		Number of establishments	Number of customers	Coverage (%)	Transaction amount % mix (%)	Change in number of customers	Change in transaction amount	Number of customers	Transaction amount % mix (%)	
I	Hospitals	approx. 8,200	7,485	91.2	11.4	+ 22	+ 2.3	7,463	10.5	
	DPC	approx. 1,760	1,735	98.5	6.8	+ 17	+ 6.6	1,718	6.0	
	Clinics	approx. 105,300	29,357	27.9	12.7	- 604	- 13.5	29,961	13.8	
Ρ	harmacies	approx. 61,300	58,885	96.1	75.8	+ 875	- 5.8	58,010	75.6	
	Total	approx. 174,800	95,727	54.8	100.0	+ 293	- 6.0	95,434	100.0	

(Excludes transactions by other companies)

Note: The number of establishments is calculated with reference to Nihon Ultmarc's national medical institution data.

Selling, general and administrative expenses (Domestic segment)

(JPY million, %)

Fiscal period	Pharmaceutio	armaceutical, al, Daichi Kase cal, Sunsho Ph	ei, Greencaps	Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical			
		23/3 2Q			22/3 2Q		
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)	
Personnel	8,939	12.7	+ 12.6	7,935	12.4	+ 6.3	
Advertising	385	0.5	- 46.4	719	1.1	+ 146.2	
Packing & freight	1,372	1.9	+ 15.5	1,187	1.9	+ 8.9	
Commissions paid	1,951	2.8	+ 71.6	1,137	1.8	+ 20.6	
R&D	5,592	7.9	+ 22.3	4,571	7.1	+ 18.7	
Depreciation	661	0.9	+ 24.9	530	0.8	+ 11.6	
Other	2,887	4.1	+ 9.7	2,633	4.1	+ 5.2	
SGA	21,789	30.9	+ 16.4	18,714	29.2	+ 12.6	

Notes: 1. Due to the consolidation of Sunsho Pharmaceutical in 2023/03 1Q, the results of 2023/03 2Q include Sunsho Pharmaceutical's SGA of JPY 1,496 million.

- 2. Goodwill amortization is not included.
- 3. Depreciation does not include portions that were reclassified as R&D expenses.
- 4. The first half period for Sunsho Pharmaceutical is from January 1 to June 30, 2022.

11

Outline of financial results for 2023/03 2Q (Overseas segment)

- Net sales : Increased due to strong B2B and B2C businesses in Europe and the weaker yen, despite the impact of business suspension at some manufacturing licensees in the U.S.
- Segment profit : Decreased due to a rise in the cost of sales ratio and an increase in SGA, despite an increase in sales
 (JPY million, %)

Fiscal period	Overseas segment (Towa HD)										
	2	2023/03 2Q		2022/03 2Q							
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)					
Net sales	19,902	100.0	+ 8.9	18,270	100.0	- 2.4					
Cost of sales	13,565	68.2	+ 12.6	12,044	65.9	- 11.1					
SGA	6,119	30.7	+ 2.8	5,950	32.6	+ 20.7					
Segment profit	217	1.1	- 21.0	274	1.5	+ 12.2					
Exchange rate	23/3 2Q	22/3 2	Q								
during period (TTM) EUR 1	JPY 134.25	JPY 129	0.82								

Note: The first half period for Towa HD is from January 1 to June 30, 2022.

FOWA

Outline of financial results for 2023/03 2Q

(Overseas segment, by region)

Europe	Net sales :	Increased due to strength in both B2B and B2C businesses, among other factors
	Segment loss :	Loss decreased due to an increase in gross margin following an increase in sales
U.S.	Net sales :	Increased due to a weaker euro against the dollar, despite business suspension at some manufacturing licensees
	Segment profit ·	Decreased due to a rise in the cost of sales ratio and an increase in SGA

Segment profit: Decreased due to a rise in the cost of sales ratio and an increase in SGA, despite an increase in sales

(JPY	mil	lion,	%)
------	-----	-------	----

Fiscal		Towa	HD Euro	pe			Towa HD U.S.					
period		23/3 2Q		22/3 2Q			23/3 2Q	22/3 2Q				
Item	(JPY million)	Percentage of net sales(%)	YOY change (%)	(JPY million)	Percentage of net sales(%)	(JPY million)	Percentage of net sales(%)	YOY change (%)	(JPY million)	Percentage of net sales(%)		
Net sales	10,932	100.0	+ 14.0	9,587	100.0	8,970	100.0	+ 3.3	8,683	100.0		
Cost of sales	6,883	63.0	+ 19.1	5,779	60.3	6,682	74.5	+ 6.7	6,265	72.2		
SGA	4,333	39.6	- 0.6	4,358	45.5	1,786	19.9	+ 12.2	1,591	18.3		
Segment profit (loss)	-284	-2.6	-	-551	-5.8	501	5.6	- 39.3	826	9.5		
Exchange				22/3 2Q								
period EU	R 1	JPY 1	34.25	JPY 12	29.82							

Note: The first half period for Towa HD is from January 1 to June 30, 2022.

Copyright 2022 TOWA PHARMACEUTICAL CO. LTD. All Rights Reserved.

Contents

1. Outline of financial results for 2023/03 2Q

2. Outline of financial results for 2023/03 2Q – Progress rate

- Consolidated Domestic segment
- Breakdown
- **Overseas segment**
- By region
- **Trend of R&D expenses**
- 3. Balance sheets, capital expenditure and depreciation
- 4. Revisions to earnings plan for 2023/03



Outline of financial results for 2023/03 2Q – Progress rate (Consolidated)

- Net sales & operating profit : Failed to achieve 1H plan due to weakness at Towa Pharmaceutical
- Ordinary profit : Failed to achieve 1H plan despite a gain on valuation of derivatives

(JPY million, %)

		23/3											
Fiscal period	2Q Re	esults		First Half Plan nounced May		Full-year Plan (announced May 13)							
Item	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	Achievement rate (%)	(JPY million)	Percentage of net sales (%)	Progress rate (%)					
Net sales	90,500	100.0	101,500	100.0	89.2	212,500	100.0	42.6					
Cost of sales	57,325	63.3	62,000	61.1	92.5	130,000	61.2	44.1					
SGA	29,954	33.1	31,500	31.0	95.1	63,500	29.9	47.2					
Operating profit	3,220	3.6	8,000	7.9	40.3	19,000	8.9	17.0					
Ordinary profit	4,609	5.1	8,000	7.9	57.6	19,000	8.9	24.3					
Profit attributable to owners of parent	2,692	3.0	4,000	3.9	67.3	12,000	5.6	22.4					

Note: The first half period for Towa HD and Sunsho Pharmaceutical is from January 1 to June 30, 2022.

Outline of financial results for 2023/03 2Q – Progress rate (Domestic segment)

- Net sales : Failed to achieve 1H plan in the domestic segment overall
- Segment profit :
- Failed to achieve 1H plan due to net sales falling short of the 1H plan and the cost of sales ratio rising beyond the expected level

(JPY million, %)

Fiscal period	Domes	Domestic segment (Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical, Sunsho Pharmaceutical)												
riscai period	2Q R	esults		First Half Plan nounced May		Full-year Plan (announced May 13)								
Item	(JPY million)	Percentage of net sales (%) (JPY million) Percentage of net sales (%) Achievement rate (%)				(JPY million)	Percentage of net sales (%)	Progress rate (%)						
Net sales	70,597	100.0	80,500	100.0	87.7	169,000	100.0	41.8						
Cost of sales	43,759	62.0	47,500	59.0	92.1	100,000	59.2	43.8						
SGA	21,789	30.9	22,800	28.3	95.6	47,500	28.1	45.9						
Segment profit	5,048	7.2	10,200	12.7	49.5	21,500	12.7	23.5						

Notes: 1. The first half period for Sunsho Pharmaceutical is from January 1 to June 30, 2022.

2. Goodwill amortization is not included.

Outline of financial results for 2023/03 2Q – Progress rate (Domestic segment, breakdown)

Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical

- Net sales : Progress rate sluggish due to a decline in prices of existing drugs following drug price revisions and a decrease in sales volume due to limited shipment of some products
- Segment profit : Progress rate sluggish due to the delayed progress of net sales and a higher-thanexpected cost of sales ratio as production efficiency fell short of expectations

Fiscal period	Full-vear Plan							Sunsho I	Pharmace	utical		
	2Q Res	sults		l-year Plan inced May 1	3)		2Q Res	ults	Full-year Plan (announced May 13)			
Item	(JPY million)	Percentage of net sales (%)	Percentage				(JPY million)	Percentage of net sales (%)		Percentage of net sales (%)	Progress rate (%)	
Net sales	60,200	100.0	144,000	100.0	41.8		10,397	100.0	25,000	100.0	41.6	
Cost of sales	35,790	59.5	80,800	56.1	44.3		7,969	76.6	19,200	76.8	41.5	
SGA	20,292	33.7	44,000	4,000 30.6			1,496	14.4	3,500	14.0	42.8	
Segment profit	4,117	6.8	19,200	13.3	21.4		931	9.0	2,300	9.2	40.5	

Notes: 1. The first half period for Sunsho Pharmaceutical is from January 1 to June 30, 2022.

2. Goodwill amortization is not included.

C Copyright 2022 TOWA PHARMACEUTICAL CO., LTD. All Rights Reserved.

TOWA

(JPY million, %)

Outline of financial results for 2023/03 2Q – Progress rate (Overseas segment)

- Net sales : Failed to achieve 1H plan due to sluggishness in the U.S. while Europe saw good progress
- Segment profit : Exceeded plan due to robust sales in Europe and a delay in R&D expenditure, among other factors

(JPY million, %)

		Overseas segment (Towa HD)												
Fiscal period	2Q R	esults		First Half Plan nounced May		Full-year Plan (announced May 13)								
Item	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	Achievement rate (%)	(JPY million)	Percentage of net sales (%)	Progress rate (%)						
Net sales	19,902	100.0	21,000	100.0	94.8	43,500	100.0	45.8						
Cost of sales	13,565	68.2	14,500 69.0		93.6	30,000	69.0	45.2						
SGA	6,119	30.7	6,700	31.9	91.3	12,000	27.6	51.0						
Segment profit (loss)	217	1.1	-200	-1.0	—	1,500	3.4	14.5						
Exchange rate (TTM)	-	23/03 2Q nange rate	2023/03 ex rate assur	-										
EUR ¹		Y 134.25	JPY 130.00											

Note: The first half period for Towa HD is from January 1 to June 30, 2022.

C Copyright 2022 TOWA PHARMACEUTICAL CO. LTD. All Rights Reserved.

Outline of financial results for 2023/03 2Q – Progress rate (Overseas segment, by region)

Europe	Net sales :	Progress rate strong as B2C business progressed as expected and B2B business saw good progress
	Segment loss :	Loss decreased compared to plan due to good progress in net sales and lower-than- expected cost of sales ratio.
U.S.	Net sales :	Progress rate sluggish due to business suspension at some manufacturing licensees, among other factors
	Segment profit :	Progress rate sluggish as gross margin fell short of expectations due to delayed progress of

net sales, and higher-than expected SGA ratio (JPY million, %)


			Towa	HD Euro	ре		Towa HD U.S.						
Fiscal period	20	Q Res	sults	Full-year Plan (announced May 13)				2Q Res	ults		I-year Plan unced May 1	13)	
Item	(JPY mill	lion)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)			(JPY million)	Percentage of net sales (%)		Percentage of net sales (%)	Progress rate (%)	
Net sales	10,9	932	100.0	20,400	100.0	53.6		8,970	100.0	23,100	100.0	38.8	
Cost of sales	6,8	383	63.0	13,200	64.7	52.1		6,682	74.5	16,800	72.7	39.8	
SGA	4,3	333	39.6	8,600	42.2	50.4		1,786	19.9	3,400	14.7	52.5	
Segment profit (loss)	-2	-284 -2.6		-1,400	-6.9	_		501	5.6	2,900	12.6	17.3	
			23/03 2Q ex rate	xchange 2023/03 exchange rate assumption									
EUR	EUR 1		JPY 134.	25	JPY 130	.00							

Note: The first half period for Towa HD is from January 1 to June 30, 2022.



TOWA PHARMACEUTICAL

Trend of R&D expenses (Consolidated)



Notes: 1. 2020/03 does not include the results of Greencaps Pharmaceutical and Towa HD.

2. 2020/03-2022/03 do not include the results of Sunsho Pharmaceutical.

20

- 1. Outline of financial results for 2023/03 2Q
- 2. Outline of financial results for 2023/03 2Q Progress rate
- 3. Balance sheets, capital expenditure and depreciation
- 4. Revisions to earnings plan for 2023/03



21

Balance sheets (Consolidated)

Sunsho Pharmaceutical was consolidated at the end of 2022/03.

(JPY million)

Item	22/9	22/3	Change	Item	22/9	22/3	Change
Cash and deposits	30,437	32,830	- 2,393	Notes and accounts payable - trade	14,802	14,834	- 32
Notes and accounts receivable - trade	42,117	42,896	- 778	Electronically recorded obligations - operating	13,242	14,242	- 999
Electronically recorded	7 700	7 074	242	Short-term borrowings	49,586	49,335	+ 250
monetary claims - operating	7,728	7,971	- 242	Current portion of bonds with share acquisition rights	_	4,150	- 4,150
Merchandise and finished goods	38,801	32,098	+ 6,702	Current portion of long-term borrowings	7,589	8,022	- 432
Other inventories	44,464	40,603	+ 3,860	Notes and accounts payable -	12,883	5,635	+ 7,247
Other current assets	12,287	10,463	+ 1,824	equipment			
Total current assets	175,836	166,864	+ 8,971	Other current liabilities	16,805	18,852	- 2,047
Buildings and structures,	53,473	52,559	+ 913	Total current liabilities	114,908	115,073	- 164
net	55,475	52,559	+ 913	Bonds with share acquisition rights	-	-	-
Machinery, equipment and vehicles, net	19,100	16,224	+ 2,875	Long-term borrowings	91,941	79,194	+ 12,746
Construction in progress	18,472	11,709	+ 6,762	Other non-current liabilities	6,073	5,659	+ 414
Goodwill	37,593	39,064	- 1,470	Total non-current liabilities	98,014	84,853	+ 13,160
Other non-current assets	47,184	45,674	+ 1,509	Total liabilities	212,923	199,927	+ 12,995
Total non-current assets	175,823	165,232	+ 10,590	Total net assets	138,736	132,169	+ 6,566
Total assets	351,659	332,097	+ 19,562	Total liabilities and net assets	351,659	332,097	19,562




Notes: 1. The exchange rate as of the end of June 2022 is indicated since the first half period for Towa HD is from January 1 to June 30, 2022.

2. The first half period for Sunsho Pharmaceutical is from January 1 to June 30, 2022.

3. The figures for 2022/03 have been retroactively adjusted to reflect the results of PPA for Sunsho Pharmaceutical.



Capital expenditure and depreciation (Consolidated)




23

ARMACEUTICAL

Outline and impact of Sunsho Pharmaceutical PPA

Consolidated balance sheet image (JPY billion)



OWA

Contents

- 1. Outline of financial results for 2023/03 2Q
- 2. Outline of financial results for 2023/03 2Q Progress rate
- 3. Balance sheets, capital expenditure and depreciation
- 4. Revisions to earnings plan for 2023/03 Consolidated Domestic segment Breakdown Overseas segment By region 2H New products to be listed on the NHI drug reimbursement price list in December



Revisions to full-year earnings plan for 2023/03 (Consolidated)

- Net sales : Revised in consideration of 1H results and 2H outlook
- Operating profit : Revised due to downward revision of sales and rise in cost of sales ratio
- Ordinary profit : Incorporating gain on valuation of derivatives generated in 1H

(JPY million, %)

				23/3			
Fiscal period			ull-year Plan November 14)			al Full-year Plar ounced May 13	
				Change from	(an	iouriced may 13	·)
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	•	(JPY million)	Percentage of net sales (%)	
Net sales	196,400	100.0	+ 18.6	- 7.6	212,500	100.0	+ 28.3
Cost of sales	125,400	63.8	+ 31.4	- 3.5	130,000	61.2	+ 36.2
SGA	62,300	31.7	+ 22.2	- 1.9	63,500	29.9	+ 24.6
Operating profit	8,700	4.4	- 54.7	- 54.2	19,000	8.9	- 1.1
Ordinary profit	10,600	5.4	- 53.4	- 44.2	19,000	8.9	- 16.4
Profit attributable to owners of parent	6,300	3.2	- 60.4	- 47.5	12,000	5.6	- 24.6
Exchange rate (TTM) EUR 1	2023/03 exchar rate assumptio (announced November 14	on 2023/03	2Q exchange rate	2023/03 exchang rate assumption (announced May	1		
	JPY 138.00	JP	Y 134.25	JPY 130.00			

Note: The consolidated fiscal year for Towa HD and Sunsho Pharmaceutical is from January 1 to December 31, 2022.

Revisions to full-year earnings plan for 2023/03 (Domestic segment)

- Net sales : Revised in consideration of 1H results and 2H outlook
- Segment profit : Revised due to a downward revision of sales and a rise in the cost of sales ratio

(JPY million, %)

F igure I is a signal	Domestic segment (Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical, Sunsho Pharmaceutical)											
Fiscal period			ıll-year Plan November 14)		Initial Full-year Plan (announced May 13)							
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	Change from initial plan	(JPY million)	Percentage of net sales (%)	YOY change (%)					
Net sales	153,000	100.0	+ 20.8	- 9.5	169,000	100.0	+ 33.4					
Cost of sales	95,200	62.2	+ 37.3	- 4.8	100,000	59.2	+ 44.2					
SGA	45,200	29.5	+ 17.5	- 4.8	47,500	28.1	+ 23.5					
Segment profit	12,600	8.2	- 33.3	- 41.4	21,500	12.7	+ 13.9					

Note: The consolidated fiscal year for Sunsho Pharmaceutical is from January 1 to December 31, 2022.

Revisions to full-year earnings plan for 2023/03 (Domestic segment, breakdown)

Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical

- Net sales : Impact of drug price revisions not expected to be compensated by the increase in sales volume
- Cost of sales : Deterioration of sales mix due to limited shipment of drugs supplemented in recent years Sunsho Pharmaceutical
- Net sales : Decreased due to adoption of new accounting standard, among other factors
- Cost of sales : Revised in consideration of a surge in raw material costs and others

(JPY million, %)

Fiscal						rmaceutic aceutical			Sunsho Pharmaceutical						
period		vised Full- ounced No	•			l Full-year P ounced May				d Full-year ed Novemb		Initial Full-year Plan (announced May 13)			
Item		Percentage of net sales (%)		Change from initial plan (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)	((JPY million)	Percentage of net sales (%)	Change from initial plan (%)	(JPY million)	Percentage of net sales (%)		
Net sales	131,500	100.0	+ 3.8	- 8.7	144,000	100.0	+ 13.7		21,500	100.0	- 14.0	25,000	100.0		
Cost of sales	78,000	59.3	+12.5	- 3.5	80,800	56.1	+ 16.5		17,200	80.0	- 10.4	19,200	76.8		
SGA	42,200	32.1	+ 9.7	- 4.1	44,000	30.6	+ 14.4		3,000	14.0	- 14.3	3,500	14.0		
Segment profit	11,300			- 41.1	19,200	13.3	+ 1.7		1,300	6.0	- 43.5	2,300	9.2		

Notes: 1. The consolidated fiscal year for Sunsho Pharmaceutical is from January 1 to December 31, 2022.

2. Goodwill amortization is not included.

ACEUTICAL

Revisions to full-year earnings plan for 2023/03 (Overseas segment)

- Net sales : Revised in consideration of 1H results and 2H outlook
- Segment profit : Revised due to a downward revision of sales and a rise in the cost of sales ratio and SGA

(JPY million, %)

			Oversea	as segmer	nt (Towa HD)					
Fiscal period			ull-year Plan November 14)		Initial Full-year Plan (announced May 13)					
ltem	(JPY million)	Percentage of net sales (%)	YOY change (%)	Change from initial plan	(JPY million)	Percentage of net sales (%)	YOY change (%)			
Net sales	43,400	100.0	+ 11.5	- 0.2	43,500	100.0	+ 11.7			
Cost of sales	30,200	69.6	+ 15.7	+ 0.7	30,000	69.0	+ 14.9			
SGA	13,100	30.2	+ 11.9	+ 9.2	12,000	27.6	+ 2.5			
Segment profit	100	0.2	- 91.1	- 93.3	1,500	3.4	+ 33.0			
Exchange rate (TTM) EUR 1	2023/03 exch rate assump (announce November	otion 2 ed ex	023/03 2Q change rate	2023/03 exch rate assump (announced Ma	tion					
	JPY 138.0)0 J	PY 134.25	JPY 130.00						

Note: The consolidated fiscal year for Towa HD is from January 1 to December 31, 2022.

Revisions to full-year earnings plan for 2023/03 (Overseas segment, by region)

- Europe Net sales : Both B2B and B2C businesses expected to remain strong
 - Segment loss : Loss expected to decrease due to upward revision of sales
- U.S.
- Net sales : Impact of business suspension at some manufacturing licensees and weakness of new products
- Segment profit : Revised due to a downward revision of sales, a rise in the cost of sales ratio owing to a rise in bulk drug prices and weakness of new products, and an increase in SGA due to the impact of exchange rates

Fiscal			Towa	HD Eui	rope				Towa HD U.S.							
period			-year Pla ovember			ull-year Planced May 1				vised Full- ounced No	•			Initial Full-year Plan (announced May 13)		
ltem	(JPY million)	Percentage of net sales (%)		Change from initial plan (%)	(JPY million)	(%) (%)			(JPY million)	Percentage of net sales (%)	YOY change (%)	Change from initial plan (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)	
Net sales	23,000	100.0	+14.2	+12.7	20,400	100.0	+1.3		20,400	100.0	+8.5	- 11.7	23,100	100.0	+22.8	
Cost of sales	14,900	64.8	+20.3	+12.9	13,200	13,200 64.7 +6.6			15,300	75.0	+11.5	- 8.9	16,800	72.7	+22.5	
SGA	8,700	37.8	+2.6	+1.2	8,600	42.2	+1.5		4,400	21.6	+36.1	+29.4	3,400	14.7	+ 5.2	
Segment profit (loss)	-600	-2.6	_	-	-1,400	-6.9	_		700	3.4	- 62.3	- 75.9	2,900	12.6	+56.3	
	ge rate (TTI EUR 1	M) ra	23/03 excl te assum (announc lovember JPY 138.	ption ed 14)	2023/03 2Q exchange				8/03 excha e assumpt unced Ma PY 130.00	ion ıy 13)						

Note: The consolidated fiscal year for Towa HD is from January 1 to December 31, 2022.



Revisions to earnings plan for 2023/03 2H

Domestic • Net sales :

Impact of drug price revisions not expected to be compensated by an increase in sales volume Segment profit : Despite a decrease in SGA due to cost reductions, revised downward due to downward revision of sales and a rise in the cost of sales ratio owing to a surge in raw material costs and a weaker yen

Overseas • Net sales :

Sluggishness in the U.S. expected to be compensated by Europe

Segment profit : Despite an upward revision of sales, revised downward due to a rise in the cost of sales ratio caused by a rise in bulk drug prices and weakness of new products, and an increase in SGA due to the impact of exchange rates (JPY million, %)

JPY 130.00

Fiscal		Dom	estic se	gment		Fiscal	Overseas segment						
period	Revi	ised 2H Plai	n	Initial 2H	Plan	period	Revi	ised 2H Pla	n	Initial 2H Plan			
	(announc	ed Novemb	er 14)	(announced	May 13)		(announc	ed Novemb	ber 14)	(announced	May 13)		
Item	(JPY million)	Percentage of net sales (%)	Change from initial plan (%)	(JPY million)	Percentage of net sales (%)	ltem	(JPY million)	Percentage of net sales (%)	Change from initial plan (%)	(JPY million)	Percentage of net sales (%)		
Net sales	82,400	100.0	- 6.9	88,500	100.0	Net sales	23,500	100.0	+ 4.4	22,500	100.0		
Cost of sales	51,400	62.4	- 2.1	52,500	59.3	Cost of sales	16,700	71.1	+ 7.7	15,500	68.9		
SGA	23,500	28.5	- 4.9	24,700	27.9	SGA	6,900	29.4	+ 30.2	5,300	23.6		
Segment profit	7,500	9.1	- 33.6	11,300	12.8	Segment profit (loss)	-100	-0.4	-	1,700	7.6		
	nge rate (TTM) EUR 1			-	assu	exchange rate umption ced May 13)							

Note: The second half period for Towa HD and Sunsho Pharmaceutical is from July 1 to December 31, 2022.

JPY 134.25

JPY 138.00

New products to be listed on NHI drug reimbursement price list in December 2022 (Domestic)

Therapeutic category	Product name	Original/representative drug name
V₂-receptor antagonist	Tolvaptan OD tablets 7.5 mg, 15 mg "Towa"	Samsca OD tablets 7.5 mg, 15 mg
Proton-pump inhibitor	Esomeprazole capsules 10 mg, 20 mg "Towa"	Nexium capsules 10 mg, 20 mg
Selective serotonin reuptake inhibitor (SSRI)	Escitalopram OD tablets 10 mg, 20 mg "Towa"	Lexapro tablets 10 mg, 20 mg (different dosage forms)
	Escitalopram tablets 10 mg, 20 mg "Towa"	Lexapro tablets 10 mg, 20 mg
Osteoporosis treatment	Ibandronate intravenous injection 1 mg syringe "Towa"	Bonviva Syringes for intravenous injection 1 mg syringe
Melatonin receptor agonist	Ramelteon tablets 8 mg "Towa"	Rozerem tablet 8 mg
Ulcerative colitis and Crohn's disease treatment	Mesalazine Sustained-release tablets 250 mg, 500 mg "Towa"	Pentasa tablet 250 mg, 500 mg
Osteoporosis treatment (active vitamin D ₃ preparation)	Edirol tablets 0.5µg, 0.75µg	-

Sales of approx. JPY 3.63 billion in total are planned for the above new products for the first fiscal year.

14 products for 7 ingredients are scheduled to be launched.

Forward-looking statements are based on targets and projections and do not offer commitments or guarantees.

Please be aware that results may differ from expectations.

Contact:

Investor Relations Group, Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.

ir@towayakuhin.co.jp TEL.06-6900-9102 FAX. 06-7177-4960

